Nepsis Capital Management Inc. lessened its holdings in Medtronic plc. (NYSE:MDT) by 22.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,283 shares of the medical technology company’s stock after selling 9,412 shares during the period. Medtronic comprises about 1.4% of Nepsis Capital Management Inc.’s portfolio, making the stock its 29th largest holding. Nepsis Capital Management Inc.’s holdings in Medtronic were worth $2,688,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the business. Captrust Financial Advisors acquired a new position in Medtronic in the second quarter valued at approximately $384,000. Wesbanco Bank Inc. lifted its stake in Medtronic by 3.1% during the second quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock worth $903,000 after purchasing an additional 308 shares in the last quarter. Dupont Capital Management Corp lifted its stake in Medtronic by 28.8% during the second quarter. Dupont Capital Management Corp now owns 74,052 shares of the medical technology company’s stock worth $6,572,000 after purchasing an additional 16,562 shares in the last quarter. Chilton Investment Co. LLC lifted its stake in Medtronic by 6.1% during the second quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock worth $2,382,000 after purchasing an additional 1,538 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its stake in Medtronic by 0.4% during the second quarter. Moors & Cabot Inc. now owns 43,227 shares of the medical technology company’s stock worth $3,842,000 after purchasing an additional 178 shares in the last quarter. Institutional investors own 81.97% of the company’s stock.
Shares of Medtronic plc. (MDT) traded up $1.10 on Friday, hitting $79.48. 6,030,879 shares of the stock traded hands, compared to its average volume of 5,510,000. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $107,580.00, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 2.19 and a beta of 0.93. Medtronic plc. has a twelve month low of $75.71 and a twelve month high of $89.72.
The business also recently announced a quarterly dividend, which was paid on Friday, January 19th. Shareholders of record on Friday, December 29th were issued a $0.46 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a yield of 2.32%. Medtronic’s dividend payout ratio (DPR) is presently 50.55%.
In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Richard Kuntz sold 78,526 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the transaction, the vice president now directly owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 136,684 shares of company stock valued at $11,582,596. 0.31% of the stock is currently owned by corporate insiders.
A number of analysts have recently weighed in on MDT shares. Bank of America raised Medtronic from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks set a $92.00 price objective on Medtronic and gave the stock a “buy” rating in a research report on Sunday, November 19th. Jefferies Group reissued a “buy” rating and issued a $99.00 target price on shares of Medtronic in a report on Thursday, November 23rd. Oppenheimer reissued a “buy” rating on shares of Medtronic in a report on Thursday, December 21st. Finally, Zacks Investment Research raised Medtronic from a “sell” rating to a “hold” rating in a report on Thursday, November 23rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $90.10.
TRADEMARK VIOLATION WARNING: “Medtronic plc. (MDT) Holdings Reduced by Nepsis Capital Management Inc.” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/11/nepsis-capital-management-inc-trims-position-in-medtronic-plc-mdt.html.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.